Immunology Update – September 10, 2025: Gout Treatment, Crohn's Disease Mapping and More скачать в хорошем качестве

Immunology Update – September 10, 2025: Gout Treatment, Crohn's Disease Mapping and More

Here’s what you need to know ⬇️ From Phase 2 trial results to microbiome-based therapy innovations, these stories are shaping the future of immunology and patient care. Let’s dive into this week’s top updates: 🧬 Innovent Biologics Announces Phase 2 Results of Tigulixostat (IBI128) in Gout Patients 💊 Yonsei University Develops Technique for Mapping Gut Bacteria and Human Genes in Crohn’s Disease 🧴 MRM Health Raises €55 Million Series B to Advance Microbiome-Based Therapies 🇺🇸 Boomerang Medical Raises $20 Million to Advance Neuromodulation in Inflammatory Bowel Disease 💉 Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn’s Disease 🌟 Incyte Launches ‘HS Truths’ Campaign to Raise Awareness of Hidradenitis Suppurativa 📢 Arcutis Biotherapeutics Submits sNDA for Zoryve Cream in Pediatric Plaque Psoriasis 💰 Onco3R Therapeutics Announces Clinical Trial Approval for SIK3 Inhibitor O3R-5671 in Autoimmune Diseases 🎗 Inmedix Raises $44,689 to Support Kids with Autoimmune Diseases at Seattle Children’s ⚡ Real-World Evidence Supports Effectiveness of Neffy® in Treating Anaphylaxis 📢 Stay Ahead in Immunology Research! ✅ Like, share, and subscribe for weekly updates on immunology breakthroughs and innovative therapies. ✅ Visit www.lqventures.com for expert healthcare insights and consulting services. ✅ Contact LucidQuest at [email protected] for strategic guidance on immunology innovations and clinical research. 🔔 Turn on notifications so you never miss an update! #Immunology #GoutTreatment #CrohnsDisease #MicrobiomeTherapies #IBD #HidradenitisSuppurativa #PsoriasisTreatment #AutoimmuneDiseases #Neffy #ImmunologyResearch #LucidQuest #MedicalInnovation #HealthcareBreakthroughs